Literature DB >> 1362807

Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo.

A Chéramy1, L Barbeito, G Godeheu, J Glowinski.   

Abstract

When applied locally to the caudate nucleus of the halothane-anaesthetized cat, riluzole (10(-5) M) markedly reduced (-57%) the spontaneous release of glutamate. This effect seems to be specific, since the efflux of the other amino acids, including aspartate was not affected. Indicating further its selective inhibitory effect on the spontaneous release of glutamate, the prolonged (90 min) application of riluzole (10(-5) M) enhanced the size of the potassium-releasable pool of glutamate, but not that of aspartate. This effect of riluzole was not noticed with classical anti-glutamatergic drugs, tested in the same conditions.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1362807     DOI: 10.1016/0304-3940(92)90597-z

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  28 in total

1.  Targeting glial physiology and glutamate cycling in the treatment of depression.

Authors:  Gerald W Valentine; Gerard Sanacora
Journal:  Biochem Pharmacol       Date:  2009-04-17       Impact factor: 5.858

Review 2.  TRPC channels and their implication in neurological diseases.

Authors:  Senthil Selvaraj; Yuyang Sun; Brij B Singh
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-03       Impact factor: 4.388

3.  Functional identification of activity-regulated, high-affinity glutamine transport in hippocampal neurons inhibited by riluzole.

Authors:  Jeffrey D Erickson
Journal:  J Neurochem       Date:  2017-05-18       Impact factor: 5.372

4.  Altered expression and uptake activity of spinal glutamate transporters after nerve injury contribute to the pathogenesis of neuropathic pain in rats.

Authors:  Backil Sung; Grewo Lim; Jianren Mao
Journal:  J Neurosci       Date:  2003-04-01       Impact factor: 6.167

5.  Effects of riluzole on electrically evoked neurotransmitter release.

Authors:  T Jehle; J Bauer; E Blauth; A Hummel; M Darstein; T M Freiman; T J Feuerstein
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

6.  Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study.

Authors:  Paul D Arnold; David R Rosenberg; Emanuela Mundo; Subi Tharmalingam; James L Kennedy; Margaret A Richter
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

7.  Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole.

Authors:  Brian P Brennan; James I Hudson; J Eric Jensen; Julie McCarthy; Jacqueline L Roberts; Andrew P Prescot; Bruce M Cohen; Harrison G Pope; Perry F Renshaw; Dost Ongür
Journal:  Neuropsychopharmacology       Date:  2009-12-02       Impact factor: 7.853

8.  Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease.

Authors:  Carlos Cepeda; Raymond S Hurst; Christopher R Calvert; Elizabeth Hernández-Echeagaray; Oanh K Nguyen; Emily Jocoy; Lindsey J Christian; Marjorie A Ariano; Michael S Levine
Journal:  J Neurosci       Date:  2003-02-01       Impact factor: 6.167

9.  Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity.

Authors:  Jianren Mao; Backil Sung; Ru-Rong Ji; Grewo Lim
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

Review 10.  Riluzole in the treatment of mood and anxiety disorders.

Authors:  Christopher Pittenger; Vladimir Coric; Mounira Banasr; Michael Bloch; John H Krystal; Gerard Sanacora
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.